Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1

J Am Coll Cardiol. 2017 Nov 14;70(20):2536-2551. doi: 10.1016/j.jacc.2017.09.1096.

Abstract

Modern cancer therapy has successfully cured many cancers and converted a terminal illness into a chronic disease. Because cancer patients often have coexisting heart diseases, expert advice from cardiologists will improve clinical outcome. In addition, cancer therapy can also cause myocardial damage, induce endothelial dysfunction, and alter cardiac conduction. Thus, it is important for practicing cardiologists to be knowledgeable about the diagnosis, prevention, and management of the cardiovascular complications of cancer therapy. In this first part of a 2-part review, we will review cancer therapy-induced cardiomyopathy and ischemia. This review is based on a MEDLINE search of published data, published clinical guidelines, and best practices in major cancer centers. With the number of cancer survivors expanding quickly, the time has come for cardiologists to work closely with cancer specialists to prevent and treat cancer therapy-induced cardiovascular complications.

Keywords: cancer therapy; cardiomyopathy; cardiovascular complication; ischemia.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Cardiovascular Diseases* / chemically induced
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / prevention & control
  • Disease Management*
  • Global Health
  • Humans
  • Incidence
  • Neoplasms / drug therapy*
  • Risk Factors

Substances

  • Antineoplastic Agents